Business Wire

ABB Powers Tourists to the Niagara Falls with First US Built All-Electric Vessels

3.5.2019 18:45:00 EEST | Business Wire | Press release

Share

Niagara Falls tour operator Maid of the Mist orders two new passenger vessels sailing on pure electric power, enabled by ABB’s technology

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190503005349/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Maid of the Mist new passenger vessels sailing on pure electric power, enabled by ABB's technology (Photo: Business Wire)

Visitors to the iconic Niagara Falls will soon be able to experience one of the US’s top landmarks emission-free. Two new Maid of the Mist passenger vessels will be powered entirely by high-capacity battery packs, becoming the first all-electric vessels ever built in the US.

The new vessels will benefit from ABB’s zero-emission technology when they start operating later this year, allowing guests to experience Niagara Falls undisturbed by engine noise, vibration or exhaust fumes from a conventional diesel engine.

Maid of the Mist, one of North America’s oldest tourist attractions, operates from April through to the first week of November, with boats departing for the base of Niagara Falls every 30 minutes, with an estimated 1.6 million guests on board annually.

“We are thrilled to be the US’s first vessel owner to add all-electric ferries to our fleet,” said Christopher M. Glynn, president of Maid of the Mist Corp. “We have chosen ABB to support us in our journey towards more sustainable operation based on their unparalleled experience in marine system integration, as well as efficient and innovative technologies for sustainable transportation.”

Maid of the Mist’s decisive move towards e-mobility signals a new era in the future of transportation and complements ABB’s commitment to power the world without consuming the earth,” said Peter Terwiesch, President of the Industrial Automation business at ABB, which offers solutions for a wide range of industries, including marine. “Reducing emissions at Niagara Falls is not only important for the natural landmark, but also proves that the technologies enabling sustainable mobility are already available today.”

Each of the vessels will be powered by a pair of battery packs with a total capacity of 316 kWh, split evenly between two catamaran hulls. Having two fully independent power systems on board will increase the resilience of operations by creating a redundancy.

The vessels will charge between every trip while passengers disembark and board. Shoreside charging will only take seven minutes, allowing the batteries to power the electric propulsion motors capable of a total 400 kW (563 HP) output. The power setup will be controlled by ABB’s integrated Power and Energy Management System (PEMS), which will optimize the energy use on board.

The batteries will be charged using hydropower – the largest single renewable energy source for electricity generation in the US, which accounts for 7 percent of the country’s total utility-scale electricity generation. The use of locally produced renewable power will make the energy cycle for the operation of the new Maid of the Mist vessels entirely emission-free.

Sustainable transportation has a crucial role in the fight against climate change, with shipping accounting for 2 to 3 percent of the world’s total greenhouse gas emissions. The International Maritime Organization, a United Nations agency responsible for regulating shipping, has set a global target to cut annual emissions by at least 50 percent by 2050 from 2008 levels.

In addition to integrating the ship-to-shore battery charging connection, ABB will supply the Maid of the Mist newbuilding project with switchboards, drives and the integrated control system, as well as the ABB Ability™ Marine Remote Diagnostic System for remote equipment monitoring and predictive maintenance. ABB Ability™ is ABB’s leading offering of digital solutions and services.

To watch the video, click here.

ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees. www.abb.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland

Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye